DuoTrav

ApprovedSmall molecule

AAlcon Research

DuoTrav is one of 41 small molecule programs targeting Ocular Hypertension. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ocular HypertensionActive, not recruiting

Open-Angle GlaucomaActive, not recruiting

Ocular HypertensionPhase 3

Active, not recruiting

Open-Angle GlaucomaApproved

Active, not recruiting

Competition

Competitive Landscape

187 competitors in Ocular Hypertension

#DrugCompanyPhaseTrials

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

9 2

Comparator: Pbo

Merck & Co.

Phase 3

2 3

DuoTrav

AAlcon Research

Approved

1 4

Ocupress

AbbVie

Phase 3

1 5

LUMIGAN

AbbVie

Phase 3

2 6

Krytantek

AbbVie

Phase 3

2 7

Bimatoprost/timolol

AbbVie

Phase 3

4 8

Preservative-Free Tafluprost

Merck & Co.

Phase 3

2 9

PRO-122

LLaboratorios Sophia S.A de C.V.

Phase 3

1 10

Reference - LUMIGAN

AAmneal Pharmaceuticals, LLC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

Safety and Efficacy Study of DuoTrav APS Versus DuoTrav

Withdrawn·AAlcon Research·Phase 3·NCT00862472

Ocular Hypertension1 trial

A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Completed·MMinistry of Health, Malaysia·Phase 3·NCT01168414·42 enrolled

GAN1 trial

Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.··NCT01206361·2,015 enrolled

Open-Angle Glaucoma1 trial

A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma

Completed·OOphthalmic Consultants Centres, Canada·Phase 4·NCT00887029·54 enrolled

Unspecified3 trials

DuoTrav APS Versus XALACOM® in Ocular Surface Health

Terminated·AAlcon Research·Phase 3·NCT00912054·240 enrolled

DuoTrav® Eye Drops As Replacement Therapy Program

Completed·AAlcon Research·Phase 4·NCT00828906·128 enrolled

Bimatoprost/Timolol Versus Travoprost/Timolol

Completed·KKasr El Aini Hospital·N/A·NCT01542710·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for DuoTrav. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DuoTrav compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DuoTrav. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alcon Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAlcon Research

DuoTrav

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Safety and Efficacy1 trial

Ocular Hypertension1 trial

GAN1 trial

Open-Angle Glaucoma1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News